Skip to main content

HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management

American Journal of Clinical Dermatology volume 20, pages 423–442 (2019)Cite this article

Abstract

Antiretroviral therapy (ART) has revolutionized the treatment and prognosis of people living with HIV (PLHIV). With increased survival and improved overall health, PLHIV are experiencing dermatologic issues both specific to HIV and common to the general population. In this new era of ART, it is crucial for dermatologists to have a strong understanding of the broad range of cutaneous disease and treatment options in this unique population. In this review, we outline the most common skin diseases in PLHIV, including HIV-associated malignancies, inflammatory conditions, and infections, and focus on the role of ART in altering epidemiology, clinical features, diagnosis, and treatment of cutaneous conditions.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. Chang Y, Cesarman E, Pessin MS, Lee F. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266(5192):1865.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Albini A, Aluigi M, Benelli R, Berti E, Biberfeld P, Blasig C, et al. Oncogenesis in HIV-infection. Int J Oncol. 1996;9(1):5–8.

    CAS  PubMed  Google Scholar 

  3. Chang Y, Ziegler J, Wabinga H, Katangole-Mbidde E, Boshoff C, Schulz T, et al. Kaposi’s sarcoma-associated herpesvirus and Kaposi’s sarcoma in Africa: Uganda Kaposi’s Sarcoma Study Group. Arch Intern Med. 1996;156(2):202–4.

    Article  CAS  PubMed  Google Scholar 

  4. Semeere AS, Busakhala N, Martin JN. Impact of antiretroviral therapy on the incidence of Kaposi’s sarcoma in resource-rich and resource-limited settings. Curr Opin Oncol. 2012;24(5):522–30.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Semeere A, Wenger M, Busakhala N, Buziba N, Bwana M, Muyindike W, et al. A prospective ascertainment of cancer incidence in sub-Saharan Africa: the case of Kaposi sarcoma. Cancer Med. 2016;5(5):914–28.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D’Souza G, et al. Cumulative incidence of cancer among HIV-infected individuals in North America. Ann Intern Med. 2015;163(7):507–18.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018.

  8. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N Engl J Med. 2007;357(13):1352–3.

    Article  CAS  PubMed  Google Scholar 

  9. Yanik EL, Achenbach CJ, Gopal S, Coghill AE, Cole SR, Eron JJ, et al. Changes in clinical context for Kaposi’s sarcoma and non-hodgkin lymphoma among people with HIV infection in the United States. J Clin Oncol. 2016;34(27):3276–83.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K, et al. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010;102(11):784–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, et al. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis. 2002;2(5):281–92.

  12. Gantt S, Kakuru A, Wald A, Walusansa V, Corey L, Casper C, et al. Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer. 2010;54(5):670–4.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gupta V, Patra S, Arava S, Sethuraman G. Hidden acral lentiginous melanoma with cutaneous metastases masquerading as Kaposi’s sarcoma in an HIV-positive Indian man. BMJ Case Rep. 2016.

  14. Berger TG, Tappero JW, Kaymen A, LeBoit PE. Bacillary (epithelioid) angiomatosis and concurrent Kaposi’s sarcoma in acquired immunodeficiency syndrome. Arch Dermatol. 1989;125(11):1543–7.

    Article  CAS  PubMed  Google Scholar 

  15. Cortes EE, Saraceni V, Medeiros D, Ribeiro I. Bacillary angiomatosis and Kaposi’s sarcoma in AIDS. AIDS Patient Care STDs. 2000;14(4):179–82.

    Article  CAS  PubMed  Google Scholar 

  16. Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults. WHO guidelines approved by the Guidelines Review Committee. Geneva. 2014.

  17. Brown DN, Langan SM, Freeman EE. Task shifting in dermatology: a call to action. JAMA Dermatol. 2017;153(11):1179–80. https://doi.org/10.1001/jamadermatol.2017.3342.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Freeman EE, Semeere A, Osman H, Peterson G, Rajadhyaksha M, Gonzalez S, et al. Smartphone confocal microscopy for imaging cellular structures in human skin in vivo. Biomed Opt Express. 2018;9(4):1906–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Krown SE, Metroka C, Wernz J. Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989;7(9):1201–7.

  20. Krown SE, Testa MA, Huang J. AIDS-related Kaposi’s sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15(9):3085–92.

  21. Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, et al. AIDS-related Kaposi’s sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era—the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naïve From Antiretrovirals. J Clin Oncol. 2003;21(15):2876–82.

    Article  PubMed  Google Scholar 

  22. Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi’s sarcoma in the era of highly active antiretroviral therapy. Lancet. 2006;367(9521):1495–502.

    Article  PubMed  Google Scholar 

  23. Krown SE. Management of AIDS-related Kaposi sarcoma. In: Yarchoan R, editor. Cancers in people with HIV and AIDS: progress and challenges. New York: Springer; 2014. p. 139–52.

    Google Scholar 

  24. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, et al. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J Clin Oncol. 2005;23(22):5224–8.

    Article  CAS  PubMed  Google Scholar 

  25. Bower M, Pria AD, Coyle C, Andrews E, Tittle V, Dhoot S, et al. Prospective stage-stratified approach to AIDS-related Kaposi’s sarcoma. J Clin Oncol. 2014;32(5):409–14.

    Article  PubMed  Google Scholar 

  26. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr (1999). 2012;60(2):150–7.

  27. Paul S, Evans R, Maurer T, Muhe LM, Freeman EE. Treatment of dermatological conditions associated with HIV/AIDS: the scarcity of guidance on a global scale. AIDS Res Treat. 2016;2016:3272483. https://doi.org/10.1155/2016/3272483.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Gbabe OF, Okwundu C I, Dedicoat M, Freeman EE. Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults. Cochrane Database of Syst Rev. 2014;8:CD003256.

  29. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16(7):2445–51.

    Article  CAS  PubMed  Google Scholar 

  30. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998;16(2):683–91.

  31. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol. 1996;14(8):2353–64.

    Article  CAS  PubMed  Google Scholar 

  32. Freeman E, Busakhala N, Asirwa FC, Regan S, Wenger M, Cheldize K, et al. Real-world use of chemotherapy for Kaposi’s sarcoma in a large community-based HIV health care network in Kenya. International Aids Society, Paris, 7 July 2017.

  33. Tulpule A, Groopman J, Saville MW, Harrington W, Friedman-Kien A, Espina BM, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002;95(1):147–54.

    Article  CAS  PubMed  Google Scholar 

  34. Gunduz K, Gunay U, Inanir I, Gencoglan G, Temiz P. Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma. J Dermatol Case Rep. 2012;6(2):52–3.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Rosen T. Limited extent AIDS-related cutaneous Kaposi’s sarcoma responsive to imiquimod 5% cream. Int J Dermatol. 2006;45(7):854–6.

    Article  PubMed  Google Scholar 

  36. Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B, et al. Treatment of AIDS-related cutaneous Kaposi’s sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. JAIDS J Acquir Immune Defic Syndr. 1999;22(3):235–46.

    Article  CAS  PubMed  Google Scholar 

  37. Beylot-Barry M, Vergier B, Masquelier B, Bagot M, Joly P, Souteyrand P, et al. The spectrum of cutaneous lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol. 1999;23(10):1208–16.

    Article  CAS  PubMed  Google Scholar 

  38. Sakib SMN, Sadler M. Dramatic treatment response of cutaneous plasmablastic lymphoma in an HIV patient: a case report. Clin Imaging. 2016;40(6):1067–9.

    Article  PubMed  Google Scholar 

  39. Corti M, Carolis LD, Solari R, Villafañe MF, Schtirbu R, Lewi D, et al. Non Hodgkin’s lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature. Braz J Infect Dis. 2010;14(1):81–5.

    PubMed  Google Scholar 

  40. Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lanoy E, Costagliola D, Engels EA. Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. Int J Cancer. 2010;126(7):1724–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Rangel J, Novoa R, Morrison C, Frank D, Kovarik C. Fistulizing Epstein-Barr virus-positive plasmablastic lymphoma in an HIV-positive man. Br J Dermatol. 2016;174(2):398–401.

    Article  CAS  PubMed  Google Scholar 

  43. Jambusaria A, Shafer D, Wu H, Al-Saleem T, Perlis C. Cutaneous plasmablastic lymphoma. J Am Acad Dermatol. 2008;58(4):676–8.

    Article  PubMed  Google Scholar 

  44. Tetzlaff MT, Nosek C, Kovarik CL. Epstein–Barr virus-associated leiomyosarcoma with cutaneous involvement in an African child with human immunodeficiency virus: a case report and review of the literature. J Cutan Pathol. 2011;38(9):731–9.

    Article  PubMed  Google Scholar 

  45. Mirvish JJ, Pomerantz RG, Falo LD, Geskin LJ. Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies. Clin Dermatol. 2013;31(4):423–31.

    Article  PubMed  Google Scholar 

  46. Poiesz B, Dube D, Dube S, Love J, Papsidero L, Uner A, et al. HTLV-II–associated cutaneous T-cell lymphoma in a patient with HIV-1 infection. N Engl J Med. 2000;342(13):930–6.

    Article  CAS  PubMed  Google Scholar 

  47. Burns MK, Cooper KD. Cutaneous T-cell lymphoma associated with HIV infection. J Am Acad Dermatol. 1993;29(3):394–9.

    Article  CAS  PubMed  Google Scholar 

  48. Yamashita M, Fujii Y, Ozaki K, Urano Y, Iwasa M, Nakamura S, et al. Human immunodeficiency virus-positive secondary syphilis mimicking cutaneous T-cell lymphoma. Diagn Pathol. 2015;10(1):185.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Saggini A, Anemona L, Chimenti S, Sarmati L, Torti C, Di Stefani A, et al. HIV-associated primary cutaneous anaplastic large cell lymphoma: a clinicopathological subset with more aggressive behavior? Case report and review of the literature. J Cutan Pathol. 2012;39(12):1100–9.

    Article  PubMed  Google Scholar 

  50. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol. 2006;54(2):189–206 (quiz 7–10).

  51. Baptista MJ, Garcia O, Morgades M, Gonzalez-Barca E, Miralles P, Lopez-Guillermo A, et al. HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. AIDS. 2015;29(7):811–8.

    Article  CAS  PubMed  Google Scholar 

  52. Bateganya MH, Stanaway J, Brentlinger PE, Magaret AS, Wald A, Orem J, et al. Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: a retrospective study on the impact of HIV infection and its treatment. J Acquir Immune Defic Syndr. 2011;56(4):312–9.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Lanoy E, Dores GM, Madeleine MM, Toro JR, Fraumeni JF Jr, Engels EA. Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS. 2009;23(3):385–93.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Zancanaro PC, McGirt LY, Mamelak AJ, Nguyen RH, Martins CR. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol. 2006;54(4):581–8.

    Article  PubMed  Google Scholar 

  55. Vin-Christian K, Epstein JH, Maurer TA, McCalmont TH, Berger TG. Photosensitivity in HIV-infected individuals. J Dermatol. 2000;27(6):361–9.

    Article  CAS  PubMed  Google Scholar 

  56. Pappert A, Grossman M, DeLeo V. Photosensitivity as the presenting illness in four patients with human immunodeficiency viral infection. Arch Dermatol. 1994;130(5):618–23.

    Article  CAS  PubMed  Google Scholar 

  57. Bilu D, Mamelak AJ, Nguyen RHN, Queiroz PC, Kowalski J, Morison WL, et al. Clinical and epidemiologic characterization of photosensitivity in HIV-positive individuals. Photodermatol Photoimmunol Photomed. 2004;20(4):175–83.

    Article  PubMed  Google Scholar 

  58. Olsen CM, Knight LL, Green AC. Risk of melanoma in people with HIV/AIDS in the pre- and post-HAART eras: a systematic review and meta-analysis of cohort studies. PLoS ONE. 2014;9(4):e95096.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Serraino D, Piselli P, Busnach G, Burra P, Citterio F, Arbustini E, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer. 2007;43(14):2117–23.

    Article  PubMed  Google Scholar 

  60. van Leeuwen MT, Vajdic CM, Middleton MG, McDonald AM, Law M, Kaldor JM, et al. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS (London, England). 2009;23(16):2183–90.

    Article  PubMed Central  Google Scholar 

  61. Rodrigues LE, Klencke BJ, Vin-Christian K, et al. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol. 2002;138(6):765–70.

    Article  PubMed  Google Scholar 

  62. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol. 2001;13(2):134–40.

    Article  CAS  PubMed  Google Scholar 

  63. Wightman F, Solomon A, Kumar SS, Urriola N, Gallagher K, Hiener B, et al. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS (London, England). 2015;29(4):504–6.

    Article  PubMed Central  Google Scholar 

  64. Davar D, Wilson M, Pruckner C, Kirkwood JM. PD-1 Blockade in Advanced melanoma in patients with hepatitis C and/or HIV. Case Rep Oncol Med. 2015;2015:737389.

    PubMed  PubMed Central  Google Scholar 

  65. Hoffmann C, Horst H, Weichenthal M, Hauschild A. Malignant melanoma and HIV infection—aggressive course despite immune reconstitution. Oncol Res Treat. 2005;28(1):35–7.

    Article  Google Scholar 

  66. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081–6.

    Article  PubMed  Google Scholar 

  67. Silverberg MJ, Leyden W, Warton EM, Quesenberry CP Jr, Engels EA, Asgari MM. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105(5):350–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Mansh M, Katz KA, Linos E, Chren M, Arron S. Association of skin cancer and indoor tanning in sexual minority men and women. JAMA Dermatol. 2015;151(12):1308–16.

    Article  PubMed  Google Scholar 

  69. Wilkins K, Dolev JC, Turner R, LeBoit PE, Berger TG, Maurer TA. Approach to the treatment of cutaneous malignancy in HIV-infected patients. Dermatol Ther. 2005;18(1):77–86.

    Article  PubMed  Google Scholar 

  70. Hausauer AK, Maurer T, Leslie KS, Parvataneni R, Stuart SE, Chren M. Recurrence after treatment of cutaneous basal cell and squamous cell carcinomas in patients infected with human immunodeficiency virus. JAMA Dermatol. 2013;149(2):239–41.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Sirera G, Videla S, Piñol M, Cañadas MP, Llatjos M, Ballesteros AL, et al. High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. AIDS. 2006;20(8):1201–4.

    Article  PubMed  Google Scholar 

  72. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500–10.

    Article  CAS  PubMed  Google Scholar 

  73. Kaplan Md JE, Benson Md C, Holmes Md PhD KK, Brooks Md JT, Pau PharmD a, Masur Md H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep. 2009;58:1–207.

  74. Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300–4.

    PubMed  PubMed Central  Google Scholar 

  75. Clinical Guidelines: adult HIV care–anal dysplasia and cancer 2007. http://www.hivguidelines.org/clinical-guidelines/adults/anal-dysplasia-and-cancer.

  76. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):1–10.

    Article  PubMed  Google Scholar 

  77. Panther L, editor. HPV-related complications. HIV update course; 2016. Boston: Beth Israel Deaconness Medical Center.

  78. Taliaferro SJ, Cohen GF. Bowen’s disease of the penis treated with topical imiquimod 5% cream. J Drugs Dermatol JDD. 2008;7(5):483–5.

    PubMed  Google Scholar 

  79. Schmitz MW, Goldberg LJ, Adler AJ. An extensive case of Bowen’s disease in an HIV-positive male. AIDS Patient Care STDs. 2007;21(2):78–80.

    Article  PubMed  Google Scholar 

  80. Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions. Dis Colon Rectum. 2002;45(4):453–8.

    Article  PubMed  Google Scholar 

  81. Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis. 2010;10(7):470–8.

    Article  CAS  PubMed  Google Scholar 

  82. Kanada KN, Schupp CW, Armstrong AW. Association between psoriasis and viral infections in the United States: focusing on hepatitis B, hepatitis C and human immunodeficiency virus. J Eur Acad Dermatol Venereol. 2013;27(10):1312–6.

    CAS  PubMed  Google Scholar 

  83. Wölfer LU, Djemadji-Oudjiel N, Hiletework M, Tebbe B, Husak R, Goerdt S, et al. HIV-associated psoriasis. Clinical and histological observations in 36 patients. Hautarzt Z Dermatol Venerol Verwandte Geb. 1998;49(3):197–202.

  84. Duvic M, Johnson TM, Rapini RP, Freese T, Brewton G, Rios A. Acquired immunodeficiency syndrome—associated psoriasis and Reiter’s syndrome. Arch Dermatol. 1987;123(12):1622–32.

    Article  CAS  PubMed  Google Scholar 

  85. Obuch ML, Maurer TA, Becker B, Berger TG. Psoriasis and human immunodeficiency virus infection. J Am Acad Dermatol. 1992;27(5 Pt 1):667–73.

    Article  CAS  PubMed  Google Scholar 

  86. Fernandes S, Pinto GM, Cardoso J. Particular clinical presentations of psoriasis in HIV patients. Int J STD AIDS. 2011;22(11):653–4.

    Article  CAS  PubMed  Google Scholar 

  87. Tull TJ, Noy M, Bunker CB, Francis ND, Morar N. Sebopsoriasis in HIV positive patients: a case series of twenty patients. Br J Dermatol. 2016.

  88. Bittencourt Mde J, Brito AC, Nascimento BA, Carvalho AH, Nascimento MD. A case of secondary syphilis mimicking palmoplantar psoriasis in HIV infected patient. An Bras Dermatol. 2015;90(3 Suppl 1):216–9.

    Article  PubMed  Google Scholar 

  89. Carnero L, Betlloch I, Ramon R, Albares MP, Guijarro J, Botella R. Psoriasis in a 5-month-old girl with HIV infection. Pediatr Dermatol. 2001;18(1):87–9.

    Article  CAS  PubMed  Google Scholar 

  90. Menon K, Van Voorhees AS, Bebo BF, Gladman DD, Hsu S, Kalb RE, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(2):291–9.

    Article  PubMed  Google Scholar 

  91. Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol. 1997;133(6):711–5.

    Article  CAS  PubMed  Google Scholar 

  92. Elliot ER, Theodoraki A, Jain LR, Marshall NJ, Boffito M, Baldeweg SE, et al. Iatrogenic Cushing’s syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies. Clin Med (Lond). 2016;16(5):412–8.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Marshall N, editor. Secondary adrenal suppression and Cushing’s syndrome caused by ritonavir boosted effects of inhaled fluticasone, injected triamcinolone and topical clobetasol: a case series. 18th British HIV Association conference; 2012 Apr 2012; Birmingham.

  94. Tripathi SV, Leslie KS, Maurer TA, Amerson EH. Psoriasis as a manifestation of HIV-related immune reconstitution inflammatory syndrome. J Am Acad Dermatol. 2015;72(1):e35–6.

    Article  PubMed  Google Scholar 

  95. Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol JEADV. 2017;31(11):e481–2.

    Article  CAS  PubMed  Google Scholar 

  96. Gallitano SM, McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016;74(5):974–80.

    Article  CAS  PubMed  Google Scholar 

  97. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.

    Article  PubMed  Google Scholar 

  98. Mathes BM, Douglass MC. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol. 1985;13(6):947–51.

    Article  CAS  PubMed  Google Scholar 

  99. Coldiron BM, Bergstresser PR. Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Arch Dermatol. 1989;125(3):357–61.

    Article  CAS  PubMed  Google Scholar 

  100. Mirmirani P, Hessol NA, Maurer TA, Berger TG, Nguyen P, Khalsa A, et al. Prevalence and predictors of skin disease in the Women’s Interagency HIV Study (WIHS). J Am Acad Dermatol. 2001;44(5):785–8.

    Article  CAS  PubMed  Google Scholar 

  101. Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy. HIV Med. 2004;5(1):50–4.

    Article  CAS  PubMed  Google Scholar 

  102. Forrestel AK, Kovarik CL, Mosam A, Gupta D, Maurer TA, Micheletti RG. Diffuse HIV-associated seborrheic dermatitis—a case series. Int J STD AIDS. 2016;27(14):1342–5.

    Article  CAS  PubMed  Google Scholar 

  103. Bason MM, Berger TG, Nesbitt LT. Pruritic papular eruption of HIV-disease. Int J Dermatol. 1993;32(11):784–9.

    Article  CAS  PubMed  Google Scholar 

  104. Boonchai W, Md RL, Manonukul J, Kulthanan K. Pruritic papular eruption in HIV seropositive patients: a cutaneous marker for immunosuppression. Int J Dermatol. 1999;38(5):348–50.

    Article  CAS  PubMed  Google Scholar 

  105. Smith KJ, Skelton HG III, James WD, Frissman DM, Barrett TL, Angritt P, et al. Papular eruption of human immunodeficiency virus disease: a review of the clinical, histologic, and immunohistochemical findings in 48 cases. Am J Dermatopathol. 1991;13(5):445–51.

    Article  CAS  PubMed  Google Scholar 

  106. Wiwanitkit V. Prevalence of dermatological disorders in Thai HIV-infected patients correlated with different CD4 lymphocyte count statuses: a note on 120 cases. Int J Dermatol. 2004;43(4):265–8.

    Article  PubMed  Google Scholar 

  107. Chua SL, Amerson EH, Leslie KS, McCalmont TH, Leboit PE, Martin JN, et al. Factors associated with pruritic papular eruption of human immunodeficiency virus infection in the antiretroviral therapy era. Br J Dermatol. 2014;170(4):832–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Hevia O, Jimenez-Acosta F, Ceballos PI, Gould EW, Penneys NS. Pruritic papular eruption of the acquired immunodeficiency syndrome: a clinicopathologic study. J Am Acad Dermatol. 1991;24(2):231–5.

    Article  CAS  PubMed  Google Scholar 

  109. Castelnuovo B, Byakwaga H, Menten J, Schaefer P, Kamya M, Colebunders R. Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome? AIDS. 2008;22(2):269–73.

    Article  PubMed  Google Scholar 

  110. Navarini AA, Stoeckle M, Navarini S, Mossdorf E, Jullu BS, Mchomvu R, et al. Antihistamines are superior to topical steroids in managing human immunodeficiency virus (HIV)-associated papular pruritic eruption. Int J Dermatol. 2010;49(1):83–6.

    Article  PubMed  Google Scholar 

  111. Bellavista S, D’Antuono A, Infusino SD, Trimarco R, Patrizi A. Pruritic papular eruption in HIV: a case successfully treated with NB-UVB. Dermatol Ther. 2013;26(2):173–5.

    Article  PubMed  Google Scholar 

  112. Pardo RJ, Bogaert MA, Penneys NS, Byrne GE, Ruiz P. UVB phototherapy of the pruritic papular eruption of the acquired immunodeficiency syndrome. J Am Acad Dermatol. 1992;26(3):423–8.

    Article  CAS  PubMed  Google Scholar 

  113. Wernham AG, Vydianath B, Chua SL. Thalidomide—a novel therapeutic approach for pruritic papular eruption of HIV. JAAD Case Rep. 2015;1(3):109–11.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Rosenthal D, LeBoit PE, Klumpp L, Berger TG. Human immunodeficiency virus-associated eosinophilic folliculitis: a unique dermatosis associated with advanced human immunodeficiency virus infection. Arch Dermatol. 1991;127(2):206–9.

    Article  CAS  PubMed  Google Scholar 

  115. Parker SR, Parker DC, McCall CO. Eosinophilic folliculitis in HIV-infected women. Am J Clin Dermatol. 2006;7(3):193–200.

    Article  PubMed  Google Scholar 

  116. Nervi SJ, Schwartz RA, Dmochowski M. Eosinophilic pustular folliculitis: a 40 year retrospect. J Am Acad Dermatol. 2006;55(2):285–9.

    Article  PubMed  Google Scholar 

  117. McCalmont TH, Altemus D, Maurer T, Berger TG. Eosinophilic folliculitis. The histologic spectrum. Am J Dermatopathol. 1995;17(5):439–46.

    Article  CAS  PubMed  Google Scholar 

  118. Rane SR, Agrawal PB, Kadgi NV, Jadhav MV, Puranik SC. Histopathological study of cutaneous manifestations in HIV and AIDS patients. Int J Dermatol. 2014;53(6):746–51.

    Article  CAS  PubMed  Google Scholar 

  119. Rajendran PM, Dolev JC, Heaphy MR Jr, Maurer T. Eosinophilic folliculitis: before and after the introduction of antiretroviral therapy. Arch Dermatol. 2005;141(10):1227–31.

    Article  PubMed  Google Scholar 

  120. Misago N, Narisawa Y, Matsubara S, Hayashi S. HIV-associated eosinophilic pustular folliculitis: successful treatment of a Japanese patient with UVB phototherapy. J Dermatol. 1998;25(3):178–84.

    Article  CAS  PubMed  Google Scholar 

  121. Nomura T, Katoh M, Yamamoto Y, Miyachi Y, Kabashima K. Eosinophilic pustular folliculitis: a published work-based comprehensive analysis of therapeutic responsiveness. J Dermatol. 2016;43(8):919–27.

    Article  CAS  PubMed  Google Scholar 

  122. Introcaso CE, Hines JM, Kovarik CL. Cutaneous toxicities of antiretroviral therapy for HIV: Part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors. J Am Acad Dermatol. 2010;63(4):549–61.

  123. Introcaso CE, Hines JM, Kovarik CL. Cutaneous toxicities of antiretroviral therapy for HIV: Part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome. J Am Acad Dermatol. 2010;63(4):563–9.

  124. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272–85.

    Article  CAS  PubMed  Google Scholar 

  125. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43–7.

  126. Naldi L, Locati F, Marchesi L, Cainelli T. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol. 1990;126(8):1103–4.

    Article  CAS  PubMed  Google Scholar 

  127. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens–Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991;127(6):839–42.

  128. Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schopf E. Incidence of Stevens–Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol. 1993;129(8):1059.

    Article  CAS  PubMed  Google Scholar 

  129. Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens–Johnson syndrome in an HIV Cohort. Am J Clin Dermatol. 2012;13(1):49–54.

    Article  PubMed  Google Scholar 

  130. Harr T, French LE. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphanet Rare Dis. 2010;5(1):39.

    Article  Google Scholar 

  131. Knight L, Muloiwa R, Dlamini S, Lehloenya RJ. Factors associated with increased mortality in a predominantly HIV-infected population with Stevens Johnson syndrome and toxic epidermal necrolysis. PLoS ONE. 2014;9(4):e93543.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Knight L, Todd G, Muloiwa R, Matjila M, Lehloenya RJ. Stevens Johnson syndrome and toxic epidermal necrolysis: maternal and foetal outcomes in twenty-two consecutive pregnant HIV infected women. PLoS ONE. 2015;10(8):e0135501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Wu P-Y, Cheng C-Y, Liu C-E, Lee Y-C, Yang C-J, Tsai M-S, et al. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. PLoS ONE. 2017;12(2):e0171596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Carr DF, Bourgeois S, Chaponda M, Takeshita LY, Morris AP, Castro EM, et al. Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. J Antimicrob Chemother. 2017.

  135. Fagot J-P, Mockenhaupt M, Bouwes-Bavinck J-N, Naldi L, Viboud C, Roujeau J-C, et al. Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. AIDS. 2001;15(14):1843–8.

    Article  CAS  PubMed  Google Scholar 

  136. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Dermatovenereol. 2003;83(1):1–9.

    Google Scholar 

  137. Colebunders R, Vanwolleghem T, Meurrens P, Moerman F. Efavirenz-associated Stevens–Johnson syndrome. Infection. 2004;32(5):306–7.

    Article  CAS  PubMed  Google Scholar 

  138. Ghislain P-D, Roujeau J-C. Treatment of severe drug reactions: Stevens–Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J. 2002;8(1).

  139. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013;68(5):693 e1–14 (quiz 706–8).

  140. Brandariz D, Smithson A, Anton-Vazquez V. Drug reaction with eosinophilia and systemic symptoms related to antiretroviral treatment in human immunodeficiency virus patients. Indian J Sex Transm Dis AIDS. 2017;38(2):163–70.

    Article  PubMed  PubMed Central  Google Scholar 

  141. Hidron AI, Moanna A, Rimland D. The rise and fall of methicillin-resistant Staphylococcus aureus infections in HIV patients. AIDS. 2011;25(7):1001–3.

    Article  PubMed  Google Scholar 

  142. Popovich KJ, Weinstein Ra, Aroutcheva A, Rice T, Hota B. Community-associated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics. Clin Infect Dis. 2010;50(7):979–87.

  143. Crum-Cianflone NF, Burgi Aa, Hale BR. Increasing rates of community-acquired methicillin-resistant Staphylococcus aureus infections among HIV-infected persons. Int J STD AIDS. 2007;18(8):521–6.

  144. Skiest DJ, Brown K, Hester J, Moore T, Crosby C, Mussa HR, et al. Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinic. HIV Med. 2006;7(6):361–8.

    Article  CAS  PubMed  Google Scholar 

  145. Talan DA, Mower WR, Krishnadasan A, Abrahamian FM, Lovecchio F, Karras DJ, et al. Trimethoprim–sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med. 2016;374(9):823–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, et al. A placebo-controlled trial of antibiotics for smaller skin abscesses. N Engl J Med. 2017;376(26):2545–55.

    Article  CAS  PubMed  Google Scholar 

  147. Krucke GW, Grimes DE, Grimes RM, Dang TD. Antibiotic resistance in Staphylococcus aureus-containing cutaneous abscesses of patients with HIV. Am J Emerg Med. 2009;27(3):344–7.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.

    Article  PubMed  Google Scholar 

  149. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367(9512):731–9.

  150. Shadyab AH, Crum-Cianflone NF. Methicillin-resistant Staphylococcus aureus (MRSA) infections among HIV-infected persons in the era of highly active antiretroviral therapy: a review of the literature. HIV Med. 2012;13(6):319–32.

    Article  CAS  PubMed  Google Scholar 

  151. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008;148(4):249–57.

    Article  PubMed  Google Scholar 

  152. Glaser P, Martins-Simoes P, Villain A, Barbier M, Tristan A, Bouchier C, et al. Demography and intercontinental spread of the USA300 community-acquired methicillin-resistant Staphylococcus aureus lineage. MBio. 2016;7(1):e02183–215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS. 2010;24(10):1549–59.

    Article  PubMed  Google Scholar 

  154. Cinti SK, Kaul DR, Sax PE, Crane LR, Kazanjian PH. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. Clin Infect Dis. 2000;30(3):511–4.

    Article  CAS  PubMed  Google Scholar 

  155. Noguchi H, Hiruma M, Kawada A, Fujimoto N, Fujioka A, Ishibashi A. A pediatric case of atypical Mycobacterium avium infection of the skin. J Dermatol. 1998;25(6):384–90.

    Article  CAS  PubMed  Google Scholar 

  156. Lugo-Janer G, Cruz A, Sanchez J. Disseminated cutaneous infection caused by Mycobacterium avium complex. JAMA Dermatol. 1990;126(8):1108–10.

    Article  CAS  Google Scholar 

  157. Kollipara R, Richards K, Tschen J, Campbell L, Tyring S, Mays S. Disseminated Mycobacterium avium complex with cutaneous lesions. J Cutan Med Surg. 2016;20(3):272–4.

    Article  CAS  PubMed  Google Scholar 

  158. Piketty C, Danic D, Weiss L. Sporotrichosislike infection caused by Mycobacterium avium in the acquired immunodeficiency syndrome. Arch Dermatol. 1993;129(10):1343–4.

    Article  CAS  PubMed  Google Scholar 

  159. Kayal JD, McCall CO. Sporotrichoid cutaneous Mycobacterium avium complex infection. J Am Acad Dermatol. 2002;47(5 suppl.).

  160. Barbaro DJ, Orcut VL, Coldiron BM. Mycobacterium avium-Mycobacterium intracellulare infection limited to the skin and lymph nodes in patients with aids. Rev Infect Dis. 1989;11(4):625–8.

    Article  CAS  PubMed  Google Scholar 

  161. Mitha M, Naicker P, Taljaard J. Cutaneous Mycobacterium kansasii infection in a patient with AIDS post initiation of antiretroviral therapy. J Infect Dev Ctries. 2011;5(7):553–5.

    Article  PubMed  Google Scholar 

  162. Curcó N, Pagerols X, Gómez L, Vives P. Mycobacterium kansasii infection limited to the skin in a patient with AIDS. Br J Dermatol. 1996;135(2):324–6.

    Article  PubMed  Google Scholar 

  163. Stellbrink H, Koperski K, Albrecht H, Greten H. Mycobacterium kansasii infection limited to skin and lymph node in a patient with AIDS. Clin Exp Dermatol. 1990;15(6):457–8.

    Article  CAS  PubMed  Google Scholar 

  164. Han SH, Kim KM, Chin BS, Choi SH, Lee HS, Kim MS, et al. Disseminated Mycobacterium kansasii infection associated with skin lesions: a case report and comprehensive review of the literature. J Korean Med Sci. 2010;25(2):304–8.

    Article  PubMed  PubMed Central  Google Scholar 

  165. Males BM, West TE, Bartholomew WR. Mycobacterium haemophilum infection in a patient with acquired immune deficiency syndrome. J Clin Microbiol. 1987;25(1):186–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  166. Rogers P, Walker R, Lane H, Witebsky F, Kovacs J, Parrillo J, et al. Disseminated Mycobacterium haemophilum infection in two patients with the acquired immunodeficiency syndrome. Am J Med. 1988;84(3):640–2.

    Article  CAS  PubMed  Google Scholar 

  167. Geisler W, Harrington R, Wallis C. Broad spectrum of dermatologic manifestations caused by Mycobacterium haemophilum infection. Arch Dermatol. 2002;138(2):229–30.

    Article  PubMed  Google Scholar 

  168. Centers for Disease C, Prevention. Sexually transmitted disease surveillance 2015. Atlanta; 2016.

  169. Diley J, Woods W, McFarland W. Are advances in treatment changing views about high-risk sex? N Engl J Med. 1997;337:501–502.

  170. Rekart M, Ndifon W, Brunham R, Dushoff J, Park SW, Rawat S, et al. A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to Treponema pallidum? Sex Transm Dis. 2017.

  171. Rompalo AM, Joesoef MR, O’donnell JA, Augenbraun M, Brady W, Radolf JD, et al. Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study. Sex Transm Dis. 2001;28(3):158–65.

  172. Hutchinson CM, Hook EW, Shepherd M, Verley J, Rompalo AM. Altered clinical presentation of early syphilis in patients with human immunodeficiency virus infection. Ann Intern Med. 1994;121(2):94–100.

    Article  CAS  PubMed  Google Scholar 

  173. Stefanie S, Rika D. Case report of three consecutive lues maligna infections in an HIV-infected patient. Int J STD AIDS. 2016;28(5):523–5.

    Google Scholar 

  174. Musher DM, Hamill RJ, Baughn RE. Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment. Ann Intern Med. 1990;113:872–81.

    Article  CAS  PubMed  Google Scholar 

  175. Balba GP, Kumar PN, James AN, Malani A, Palestine AG, Welch JN, et al. Ocular syphilis in HIV-positive patients receiving highly active antiretroviral therapy. Am J Med. 2006;119(5):448.e21–448.e25.

  176. Neurosyphilis and ocular syphilis in patients with concurrent human immunodeficiency virus infection. 1989. p. 175–80.

  177. Centers for Disease C, Prevention. Discordant results from reverse sequence syphilis screening—five laboratories, United States, 2006–2010. Morb Mortal Wkly Rep. 2011;60(5):872–5.

  178. Jurado RL, Campbell J, Martin PD. Prozone phenomenon in secondary syphilis: has its time arrived? Arch Intern Med. 1993;153(21):2496–8.

    Article  CAS  PubMed  Google Scholar 

  179. Patel P, Bush T, Mayer KH, Desai S, Henry K, Overton ET, et al. Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States. Sex Transm Dis. 2012;39(2):154–60.

    Article  PubMed  PubMed Central  Google Scholar 

  180. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 2002;185(1):45–52.

    Article  PubMed  Google Scholar 

  181. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2005;2006(20):73–83.

    Google Scholar 

  182. Heng MC, Heng SY, Allen SG. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet. 1994;343(8892):255–8.

    Article  CAS  PubMed  Google Scholar 

  183. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362(5):427–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. Baeten JM, Strick LB, Lucchetti A, Whittington WLH, Sanchez J, Coombs RW, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis. 2008;198(12):1804–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  185. Zuckerman Ra, Lucchetti A, Whittington WLH, Sanchez J, Coombs RW, Zuñiga R, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis. 2007;196(10):1500–8.

  186. Nagot N, Ouédraogo A, Foulongne V, Konaté I, Weiss HA, Vergne L, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007;356(8):790–9.

    Article  CAS  PubMed  Google Scholar 

  187. Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, Legoff J, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS (London, England). 2009;23(4):461–9.

    Article  CAS  PubMed Central  Google Scholar 

  188. Pere H, Rascanu A, LeGoff J, Matta M, Bois F, Lortholary O, et al. Herpes simplex virus type 2 (HSV-2) genital shedding in HSV-2-/HIV-1-co-infected women receiving effective combination antiretroviral therapy. Int J STD AIDS. 2016;27(3):178–85.

    Article  CAS  PubMed  Google Scholar 

  189. Posavad CM, Wald A, Kuntz S, Huang ML, Selke S, Krantz E, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis. 2004;190(4):693–6.

    Article  PubMed  Google Scholar 

  190. Bagdades EK, Pillay D, Squire SB, O’Neil C, Johnson MA, Griffiths PD. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS (London, England). 1992;6(11):1317–20.

    Article  CAS  Google Scholar 

  191. Beasley KL, Cooley GE, Kao GF, Lowitt MH, Burnett JW, Aurelian L. Herpes simplex vegetans: atypical genital herpes infection in a patient with common variable immunodeficiency. J Am Acad Dermatol. 1997;37(5, Part 2):860–3.

  192. Wald A, Huang M-L, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis. 2003;188(9):1345–51.

    Article  CAS  PubMed  Google Scholar 

  193. Ozcan A, Senol M, Saglam H, Seyhan M, Durmaz R, Aktas E, et al. Comparison of the Tzanck test and polymerase chain reaction in the diagnosis of cutaneous herpes simplex and varicella zoster virus infections. Int J Dermatol. 2007;46(11):1177–9.

    Article  PubMed  Google Scholar 

  194. Lingappa JR, Celum C. Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection. 2007. p. 155–74.

  195. Meyers JD, Wade JC, Mitchell CD, Saral R, Lietman PS, Durack DT, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med. 1982;73(1 Part 1):229–35.

  196. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ, et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS. 2002;13(1):12–21.

    Article  CAS  PubMed  Google Scholar 

  197. Romanowski B, Fy A, Ay M, Ea L, Je P, Rl S. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. AIDS. 2000:1211–7.

  198. Workowski KA, Bolan GA, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep/Centers Dis Control. 2015;64(RR-03):1–137.

  199. Schacker T, Hu HL, Koelle DM, Zeh J, Saltzman R, Boon R, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(1):21–8.

  200. DeJesus E, Wald A, Warren T, Schacker TW, Trottier S, Shahmanesh M, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188(7):1009–16.

    Article  CAS  PubMed  Google Scholar 

  201. Lalezari J, Schacker T, Feinberg J, Gathe J, Lee S, Cheung T, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis. 1997;176(4):892–8.

    Article  CAS  PubMed  Google Scholar 

  202. Wanat KA, Gormley RH, Rosenbach M, Kovarik CL. Intralesional cidofovir for treating extensive genital verrucous herpes simplex virus infection. JAMA Dermatol. 2013;149(7):881–3.

    Article  PubMed  Google Scholar 

  203. Castelo-Soccio L, Bernardin R, Stern J, Goldstein SA, Kovarik C. Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir. Arch Dermatol. 2010;146(2):124–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  204. Veenstra J, Krol A, van Praag RM, Frissen PH, Schellekens PT, Lange JM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS. 1995;9(10):1153–8.

    Article  CAS  PubMed  Google Scholar 

  205. Buchbinder SP, Katz MH, Hessol NA, Liu JY, O’Malley PM, Underwood R, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis. 1992;166(5):1153–6.

    Article  CAS  PubMed  Google Scholar 

  206. Grabar S, Tattevin P, Selinger-Leneman H, De La Blanchardiere A, De Truchis P, Rabaud C, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2015;60(8):1269–77.

    Article  PubMed  Google Scholar 

  207. Levin MJ, Anderson JP, Seage GR 3rd, Williams PL. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr. 2009;50(2):182–91.

    Article  PubMed  PubMed Central  Google Scholar 

  208. Martínez E, Gatell J, Morán Y, Aznar E, Buira E, Guelar A, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis. 1998;27(6):1510–3.

    Article  PubMed  Google Scholar 

  209. Domingo P, Torres OH, Ris J, Vazquez G. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med. 2001;110(8):605–9.

    Article  CAS  PubMed  Google Scholar 

  210. Feller L, Wood NH, Lemmer J. Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2007;104(4):455–60.

    Article  Google Scholar 

  211. Veenstra J, Van Praag RME, Krol A, Wertheim Van Dillen PME, Weigel HM, Schellekens PTA, et al. Complications of varicella zoster virus reactivation in HIV-infected homosexual men. AIDS. 1996;10(4):393–9.

  212. Gebo Ka, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr (1999). 2005;40(2):169–74.

  213. Popara M, Pendle S, Sacks L, Smego RA, Mer M. Varicella pneumonia in patients with HIV/AIDS. Int J Infect Dis. 2002;6(1):6–8.

    Article  PubMed  Google Scholar 

  214. Levin MJ, Gershon AA, Weinberg A, Blanchard S, Nowak B, Palumbo P, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139(2):305–10.

    Article  CAS  PubMed  Google Scholar 

  215. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC MMWR Recomm Rep. 2007;56(RR-4):1–40.

  216. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2013;58(3):e44–100.

    Article  PubMed  Google Scholar 

  217. Laxmisha C, Thappa DM, Jaisankar TJ. Clinical profile of molluscum contagiosum in children versus adults. Dermatol Online J. 2003;9(5):1–9.

    PubMed  Google Scholar 

  218. Petersen CS, Gerstoft J. Molluscum contagiosum in HIV-infected patients. Dermatology (Basel, Switzerland). 1992;184(1):19–21.

    Article  CAS  Google Scholar 

  219. Husak R, Garbe C, Orfanos CE. Mollusca contagiosa in HIV-patients. Clinical manifestations, relation to the immunological status and prognostic significance. Hautarzt. 1997;48(2):103–9.

  220. Schwartz JJ, Myskowski PL. Molluscum contagiosum in patients with human immunodeficiency virus infection. A review of twenty-seven patients. J Am Acad Dermatol. 1992;27(4):583–8.

  221. Calista D, Boschini A, Landi G. Resolution of disseminated molluscum contagiosum with highly active anti-retroviral therapy (HAART) in patients with AIDS. Eur J Dermatol. 1999;9(3):211–3.

    CAS  PubMed  Google Scholar 

  222. Schulz D, Sarra GM, Koerner UB, Garweg JG. Evolution of HIV-1-related conjunctival molluscum contagiosum under HAART: report of a bilaterally manifesting case and literature review. 2004. p. 951–5.

  223. Chatterjee S, Banerjee M, Bhattacharya S. Giant molluscum contagiosum: an unusual presenting complaint of paediatric HIV disease. Trop Doct. 2015;45(2):148–50.

    Article  PubMed  Google Scholar 

  224. Bachmeyer C, Moguelet P, Baud F, Lescure F. Efflorescence of facial molluscum contagiosum as a manifestation of immune reconstitution inflammatory syndrome in a patient with AIDS. Eur J Dermatol. 2009;19(3):257–8.

    PubMed  Google Scholar 

  225. Pereira B, Fernandes C, Nachiambo E, Catarino MC, Rodrigues A, Cardoso J. Exuberant molluscum contagiosum as a manifestation of the immune reconstitution inflammatory syndrome. Dermatol Online J. 2007;13(2).

  226. Yang H, Li C, Hsieh F, Liu C, Lee J, Yang C. Molluscum contagiosum-associated immune reconstitution inflammatory syndrome in human immunodeficiency virus infection. Dermatol Sin. 2016;34(4):196–9.

    Article  Google Scholar 

  227. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis. 2006;42(3):418–27.

    Article  CAS  PubMed  Google Scholar 

  228. Nyagol J, Leucci E, Onnis A, De Falco G, Tigli C, Sanseverino F, et al. The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther. 2006;5(6):684–90.

    Article  CAS  PubMed  Google Scholar 

  229. Nicol AF, Pires ARC, de Souza SR, Nuovo GJ, Grinsztejn B, Tristão A, et al. Cell-cycle and suppressor proteins expression in uterine cervix in HIV/HPV co-infection: comparative study by tissue micro-array (TMA). BMC Cancer. 2008;8:289.

  230. Afesllari E, Miller TJ, Huchital MJ, King CM, Johnston JS, Barbosa P. Reduction in size and number of plantar verrucae in human immunodeficiency virus-infected individuals after the implementation of highly active antiretroviral therapy. J Am Podiatr Med Assoc. 2015;105(5):401–6.

    Article  PubMed  Google Scholar 

  231. Massad LS, Silverberg MJ, Springer G, Minkoff H, Hessol N, Palefsky JM, et al. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol. 2004;190(5):1241–8.

    Article  CAS  PubMed  Google Scholar 

  232. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS (London, England). 2008;22(10):1203–11.

    Article  Google Scholar 

  233. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10(12):1152–9.

    Article  CAS  PubMed  Google Scholar 

  234. Gormley RH, Groft CM, Miller CJ, Kovarik CL. Digital squamous cell carcinoma and association with diverse high-risk human papillomavirus types. J Am Acad Dermatol. 64(5):981–5.

  235. Rodriguez O, Kovarik CL. Spectrum and progression of disease from condyloma to aggressive anogenital squamous cell carcinoma in 3 HIV-positive patients. JAAD Case Rep. 2016;2(1):47–50.

    Article  PubMed  PubMed Central  Google Scholar 

  236. Zancanaro PCQ, McGirt LY, Mamelak AJ, Nguyen RHn, Martins CR. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol. 2006;54(4):581–8.

  237. Barzegar C, Paul C, Saiag P, Cassenot P, Bachelez H, Autran B, et al. Epidermodysplasia verruciformis-like eruption complicating human immunodeficiency virus infection. Br J Dermatol. 1998;139(1):122–7.

    Article  CAS  PubMed  Google Scholar 

  238. Jacobelli S, Laude H, Carlotti A, Rozenberg F, Deleuze J, Morini J-P, et al. Epidermodysplasia verruciformis in human immunodeficiency virus-infected patients: a marker of human papillomavirus-related disorders not affected by antiretroviral therapy. Arch Dermatol. 2011;147(5):590–6.

    Article  PubMed  Google Scholar 

  239. Morrison C, Eliezri Y, Magro C, Nuovo GJ. The histologic spectrum of epidermodysplasia verruciformis in transplant and AIDS patients. J Cutan Pathol. 2002;29(8):480–9.

    Article  PubMed  Google Scholar 

  240. Olivier C, Robert PD, Daihung D, Urba G, Catalin MP, Hywel W, et al. What is the evidence for effective treatments of acquired epidermodysplasia verruciformis in HIV-infected patients? Arch Dermatol. 2010;146(8):903–5.

    Google Scholar 

  241. Rallis E, Paparizos V, Kyriakis K, Katsambas A. Treatment of epidermodysplasia verruciformis in human immunodeficiency virus-positive patients. J Eur Acad Dermatol Venereol. 2009;23(2):195–6.

    Article  CAS  PubMed  Google Scholar 

  242. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984;311(6):354–8.

    Article  CAS  PubMed  Google Scholar 

  243. Greenspan D, Gange SJ, Phelan JA, Navazesh M, Alves MEAF, MacPhail LA, et al. Incidence of oral lesions in HIV-1-infected women: reduction with HAART. J Dent Res. 2004;83(2):145–50.

    Article  CAS  PubMed  Google Scholar 

  244. Patel PK, Erlandsen JE, Kirkpatrick WR, Berg DK, Westbrook SD, Louden C, et al. The changing epidemiology of oropharyngeal candidiasis in patients with HIV/AIDS in the era of antiretroviral therapy. AIDS Res Treat. 2012;2012.

  245. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):409–17.

    Article  PubMed  Google Scholar 

  246. Costa JEF, Neves RP, Delgado MM, Lima-Neto RG, Morais VMS, Coêlho MRCD. Dermatophytosis in patients with human immunodeficiency virus infection: clinical aspects and etiologic agents. Acta Trop. 2015;150:111–5.

    Article  CAS  PubMed  Google Scholar 

  247. Aly R, Berger T. Common superficial fungal infections in patients with AIDS. Clin Infect Dis. 1996;22(Suppl 2):S128–32.

    Article  PubMed  Google Scholar 

  248. Marukutira T, Huprikar S, Azie N, Quan SP, Meier-Kriesche HU, Horn DL. Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the prospective antifungal therapy alliance registry, a multicenter, observational study. HIV/AIDS Res Palliat Care. 2014;6:39–47.

    Article  Google Scholar 

  249. Picon L, Vaillant L, Duong T, Lorette G, Bacq Y, Besnier JM, et al. Cutaneous cryptococcosis resembling molluscum contagiosum: a first manifestation of AIDS. Acta Dermatovenereol. 1989;69(4):365–7.

    CAS  Google Scholar 

  250. Tomasini C, Caliendo V, Puiatti P, Bernengo M. Granulomatous-ulcerative vulvar cryptococcosis in a patient with advanced HIV disease. J Am Acad Dermatol. 1997;37(1):116–7.

    Article  CAS  PubMed  Google Scholar 

  251. Cohen PR, Grossman ME. Recognizing skin lesions of systemic fungal infections in patients with AIDS. Am Fam Phys. 1994;49(7):1627–34.

    CAS  Google Scholar 

  252. Antinori S, Ridolfo AL, Fasan M, Magni C, Galimberti L, Milazzo L, et al. AIDS-associated cryptococcosis: a comparison of epidemiology, clinical features and outcome in the pre- and post-HAART eras. Experience of a single centre in Italy. HIV Med. 2009;10(1):6–11.

  253. Ampel NM. Coccidioidomycosis in persons infected with HIV type 1. Clin Infect Dis. 2005;41(8):1174–8.

    Article  PubMed  Google Scholar 

  254. Cohen PR, Bank DE, Silvers DN, Grossman ME. Cutaneous lesions of disseminated histoplasmosis in human immunodeficiency virus-infected patients. J Am Acad Dermatol. 1990;23(3 Pt 1):422–8.

    Article  CAS  PubMed  Google Scholar 

  255. Kawila R, Chaiwarith R, Supparatpinyo K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis. 2013;13(1):464.

    Article  PubMed  PubMed Central  Google Scholar 

  256. Breton G, Adle-Biassette H, Therby A, Ramanoelina J, Choudat L, Bissuel F, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS. 2006;20:119–21.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge Ms. Julia Foote (Massachusetts General Hospital) for her assistance in editing the manuscript.

Author information

Affiliations

  1. Weill Cornell Medical College, Massachusetts General Hospital, 1300 York Avenue, New York, NY, 10021, USA

    Khatiya Chelidze

  2. Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Bartlett Hall 6R, Boston, MA, 02114, USA

    Cristina Thomas & Esther Ellen Freeman

  3. Department of Dermatology, University of California, San Francisco, 505 Paranassus Avenue, San Francisco, CA, 94143, USA

    Aileen Yenting Chang

  4. Medical Practice Evaluation Center, Mongan Institute, Massachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, MA, 02114, USA

    Esther Ellen Freeman

Authors
  1. Khatiya Chelidze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aileen Yenting Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Esther Ellen Freeman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Esther Ellen Freeman.

Ethics declarations

Funding

Dr. Freeman’s effort on this manuscript was supported by the Dermatology Foundation and NIH K23 AI136579.

Conflict of interest

Khatiya Chelidze has no conflicts to disclose. Cristina Thomas has no conflicts to disclose. Aileen Yenting Chang has no conflicts to disclose. Esther Ellen Freeman has no conflicts to disclose.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chelidze, K., Thomas, C., Chang, A.Y. et al. HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management. Am J Clin Dermatol 20, 423–442 (2019). https://doi.org/10.1007/s40257-019-00422-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-019-00422-0